2024
DOI: 10.1016/j.gendis.2023.04.035
|View full text |Cite
|
Sign up to set email alerts
|

Integrative transcriptome analysis identifies MYBL2 as a poor prognosis marker for osteosarcoma and a pan-cancer marker of immune infiltration

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 45 publications
0
0
0
Order By: Relevance
“…Elevated expression of MYBL2 in various tumors is often associated with poor prognosis ( 45 , 46 ), rendering it a potential therapeutic target in cancer treatment. As a prognostic indicator of unfavorable outcomes in osteosarcoma and a universal marker for immune infiltration across various cancers, MYBL2 exerts regulatory control over proliferation, tumor advancement, and immune cell infiltration within osteosarcoma and broader cancer contexts ( 47 ). In clear cell renal carcinoma, MYBL2 promotes malignant characteristics and impedes apoptosis through activation of the hedgehog signaling pathway ( 48 ).…”
Section: Discussionmentioning
confidence: 99%
“…Elevated expression of MYBL2 in various tumors is often associated with poor prognosis ( 45 , 46 ), rendering it a potential therapeutic target in cancer treatment. As a prognostic indicator of unfavorable outcomes in osteosarcoma and a universal marker for immune infiltration across various cancers, MYBL2 exerts regulatory control over proliferation, tumor advancement, and immune cell infiltration within osteosarcoma and broader cancer contexts ( 47 ). In clear cell renal carcinoma, MYBL2 promotes malignant characteristics and impedes apoptosis through activation of the hedgehog signaling pathway ( 48 ).…”
Section: Discussionmentioning
confidence: 99%
“…Elevated expression of MYBL2 in various tumors is often associated with poor prognosis (45,46), rendering it a potential therapeutic target in cancer treatment. As a prognostic indicator of unfavorable outcomes in osteosarcoma and a universal marker for immune infiltration across various cancers, MYBL2 exerts regulatory control over proliferation, tumor advancement, and immune cell infiltration within osteosarcoma and broader cancer contexts (47). In clear cell renal carcinoma, MYBL2 promotes malignant characteristics and impedes apoptosis through activation of the hedgehog signaling pathway (48).…”
Section: Discussionmentioning
confidence: 99%